We are live on
!
Find out more
BLAM
Bourne Lent Asset Management Portfolio holdings
AUM
$289M
1-Year Est. Return
30.86%
This Fund
S&P 500
This Quarter
Est. Return
-0.23%
1 Year Est. Return
+30.86%
3 Year Est. Return
+76.09%
5 Year Est. Return
+95.46%
10 Year Est. Return
+670.42%
AUM
$348M
AUM Growth
-$7.67M
(-2.2%)
Cap. Flow
-$4.17M
Cap. Flow
% of AUM
-1.2%
Top 10 Holdings %
Top 10 Hldgs %
74.93%
Holding
62
New
–
Increased
2
Reduced
8
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacific Biosciences
PACB
|
+$119K |
| 2 |
NVTA
Invitae Corporation
NVTA
|
+$23.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Idexx Laboratories
IDXX
|
+$1.56M |
| 2 |
Apple
AAPL
|
+$1.22M |
| 3 |
Adobe
ADBE
|
+$944K |
| 4 |
Microsoft
MSFT
|
+$247K |
| 5 |
Annovis Bio
ANVS
|
+$231K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 39.46% |
| 2 | Healthcare | 32.2% |
| 3 | Communication Services | 12.12% |
| 4 | Consumer Discretionary | 5.75% |
| 5 | Industrials | 3.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Visa
V
$677B
| $1.94M | 0.56% |
8,700
| – | – |
|
27
Wayfair
W
$14.6B
| $1.85M | 0.53% |
7,229
| – | – |
|
28
Mastercard
MA
$493B
| $1.74M | 0.5% |
4,998
| – | – |
|
29
Pfizer
PFE
$153B
| $1.66M | 0.48% |
38,679
| – | – |
|
30
Berkshire Hathaway Class A
BRK.A
$1.12T
| $1.65M | 0.47% |
4
| – | – |
|
31
Illumina
ILMN
$28.4B
| $1.3M | 0.37% |
3,290
| – | – |
|
32
Amgen
AMGN
$222B
| $1.09M | 0.31% |
5,137
| – | – |
|
33
Eli Lilly
LLY
$1.06T
| $942K | 0.27% |
4,076
| – | – |
|
34
Public Service Enterprise Group
PEG
$37.7B
| $921K | 0.26% |
15,122
| – | – |
|
35
PepsiCo
PEP
$190B
| $846K | 0.24% |
5,625
| – | – |
|
36
Boston Scientific
BSX
$71.5B
| $769K | 0.22% |
17,719
| – | – |
|
37
Lowe's Companies
LOW
$125B
| $710K | 0.2% |
3,500
| – | – |
|
38
Intel
INTC
$513B
| $612K | 0.18% |
11,490
| – | – |
|
39
Microchip Technology
MCHP
$46B
| $609K | 0.17% |
7,930
| – | – |
|
40
Verizon
VZ
$196B
| $579K | 0.17% |
10,719
| – | – |
|
41
Gilead Sciences
GILD
$165B
| $571K | 0.16% |
8,180
| – | – |
|
42
Procter & Gamble
PG
$339B
| $488K | 0.14% |
3,491
| – | – |
|
43
Home Depot
HD
$355B
| $476K | 0.14% |
1,450
| – | – |
|
44
Merck
MRK
$318B
| $448K | 0.13% |
5,967
| – | – |
|
45
Intuit
INTU
$89B
| $432K | 0.12% |
800
| – | – |
|
46
CenterPoint Energy
CNP
$26.8B
| $417K | 0.12% |
16,966
| – | – |
|
47
Cognizant
CTSH
$26B
| $371K | 0.11% |
5,000
| – | – |
|
48
EOG Resources
EOG
$70.7B
| $325K | 0.09% |
4,051
| – | – |
|
49
NVIDIA
NVDA
$5.42T
| $320K | 0.09% |
15,440
| – | – |
|
50
Boeing
BA
$185B
| $314K | 0.09% |
1,428
| – | – |
|
Similar funds
PIA
CCC
GIM
PSA
SI
FFA
OCM
ODFS
Bourne Lent Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Bourne Lent Asset Management held 62 positions worth $348M, down 2.2% from $356M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 1.6%. Bourne Lent Asset Management opened no new positions and exited 1, leaving the 62-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 39% of assets, up from 39% a quarter earlier, followed by Healthcare and Communication Services.
- Bourne Lent Asset Management added most to Pacific Biosciences in Q3 2021, an estimated $119K increase.
- Bourne Lent Asset Management's biggest Q3 2021 reduction was Idexx Laboratories, cutting an estimated $1.56M.
- Bourne Lent Asset Management fully exited Annovis Bio in Q3 2021, selling an estimated $231K.
- Bourne Lent Asset Management's ten largest holdings make up 75% of its $348M portfolio in Q3 2021.
- Bourne Lent Asset Management opened 0 new positions and closed 1 in Q3 2021.
- Bourne Lent Asset Management's portfolio value fell 2.2% quarter-over-quarter to $348M.
Based on Bourne Lent Asset Management's 13F filing for Q3 2021, filed 20 Oct 2021.